摘要
目的探讨根治性肾切除术联合应用α-干扰素治疗肾癌的临床治疗效果。方法对24例肾癌患者进行开放根治性肾切术,术后应用α-干扰素,以T淋巴细胞亚群分类CD3、CD4、CD8、CD4/CD8为疗效评价的主要指标,比较α-干扰素使用前、后以及与正常人群T淋巴细胞亚群的差异。结果肾癌根治术后患者使用α-干扰素前(术后1周),T淋巴细胞亚群CD3、CD4、CD8、CD4/CD8水平和正常人群比较显著降低,差异均有统计学意义(t分别=2.91、3.26、2.32、2.83,P均<0.05);α-干扰素使用前后的T淋巴细胞亚群CD3、CD4、CD8、CD4/CD8比较,除CD4/CD8外,差异亦均有统计学意义(t分别=2.79、3.04、2.21,P均<0.05),而α-干扰素使用后,T淋巴细胞亚群CD3、CD4、CD8、CD4/CD8水平和正常人群相近,差异均无统计学意义(t分别=0.86、1.03、0.77、0.52,P均>0.05)。结论根治性肾切除术联合应用α-干扰素治疗肾癌,有利于患者术后免疫功能的恢复,增强机体抗肿瘤能力,且副反应轻。
Objective To study the effects of united usage of radical nephrectomy and α- interferon on the treatment of renal cell carcinoma. Methods Twenty four cases of renal cell carcinoma were treated by radical nephrectomy and α- interferon. The T - lymphocyte subsets CD3, CD4, CD8 and the ratio of CD4/CD8 were used as the main indexes. The levels of CD3, CD4, CD8 and CD4/CD8 after α- interferon treatment were compared with the results before the α- interferon treatment and the healthy people. Results The levels of CD3, CD4, CD8 were significantly different before and after united treatment （ t = 2.79,3.04,2.21, P 〈 0.05）. The T- lymphocyte subsets CD3,CD4,CD8, and CD4/ CD8 before the united treatment were significantly lower compared with the healthy people （ t = 2.91,3.26,2.32,2.83, P 〈 0.05）. Conclusion United usage of radical nephrectomy and α- interferon can restore immunity of patients so as to enhance the treatment efficacy.
出处
《全科医学临床与教育》
2007年第4期291-292,295,共3页
Clinical Education of General Practice
关键词
肾癌
生物治疗
干扰素
renal cell carcinoma
biotherapy
interferon
